Dream Team targets molecular factors common in women’s cancers

http://youtu.be/DIlb62mP0Uk First clinical trials begin soon to test new drugs against ovarian, endometrial and breast cancers that harbor dysfunctional PI3K pathways. MD Anderson's Gordon Mills explains.